

Prevalence of Angiotensin II Type 1 Receptor Antibodies in Persons With Hypertension and Relation to Blood Pressure and Medication

Mary Carmelle Philogene,^{1,*} Dingfen Han,² Flor Alvarado,^{2,3} Neal S. Fedarko,⁴ Alan B. Zonderman,⁵ Michele K. Evans,⁵ and Deidra C. Crews^{2,3}

BACKGROUND

We aimed to determine the prevalence of antibodies against angiotensin II type 1 receptor (AT1Rab) in hypertensive adults and elucidate the relation of antihypertensive medication type to blood pressure (BP) among persons with and without AT1Rab.

METHODS

Sera from participants in the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study with hypertension were tested for AT1Rab using a commercial Enzyme-linked immunosorbent assay (ELISA) (One Lambda; positive ≥ 17 units/ml). BP measurements, uncontrolled BP (systolic BP ≥ 140 and/or diastolic BP ≥ 90 mm Hg), and effect of BP medication type were compared for AT1Rab positive (+) vs. negative (–) participants using descriptive statistics and multivariable regression.

RESULTS

One hundred and thirty-two (13.1%) participants were AT1Rab+. Compared with AT1Rab–, AT1Rab+ persons were more likely to be white (47% vs. 36.7%; $P = 0.03$) but had similar comorbid disease burden. In

models adjusting for age, sex, and race, AT1Rab+ persons had higher diastolic BP ($\beta = 2.61$ mm Hg; SE = 1.03; $P = 0.01$) compared with AT1Rab– participants. Rates of uncontrolled BP were similar between the groups. AT1Rab+ persons on an angiotensin receptor blocker (ARB; $n = 21$) had a mean of 10.5 mm Hg higher systolic BP (SE = 4.56; $P = 0.02$) compared with AT1Rab+ persons using other BP medications. The odds of uncontrolled BP among AT1Rab+ participants on an ARB was 2.05 times that of those on other medications. AT1Rab– persons prescribed an angiotensin-converting enzyme inhibitor (ACEi) had 1.8 mm Hg lower diastolic BP (SE = 0.81; $P = 0.03$) than AT1Rab– persons not prescribed an ACEi.

CONCLUSIONS

AT1Rab was prevalent among hypertensive adults and was associated with higher BP among persons on an ARB.

Keywords: angiotensin II type 1 receptor antibody; blood pressure; health disparities; hypertension

doi:10.1093/ajh/hpaa071

The renin and angiotensin system has been the target of several therapeutic drugs designed to regulate blood pressure (BP).^{1–3} However, evidence shows variability in the efficacy of these therapies based on patient characteristics.^{4–7} Within renin and angiotensin system, angiotensin II and the angiotensin receptors are central to maintenance of BP control.^{8,9} Under normal conditions, cellular homeostasis is maintained by alternate vasoconstriction and vasodilation of the arteries as angiotensin II binds to its receptors, angiotensin II type 1 (AT1R) and type 2 (AT2R), respectively. When angiotensin II binds to AT1R, in addition to vasoconstriction, it mediates other important physiological functions such as salt and water retention, aldosterone secretion, and

vascular remodeling.¹ Under stressful conditions that lead to loss of homeostasis, a more persistent or recurrent activation of AT1R by its ligand, angiotensin II, results in extended vascular constriction, inflammation, and development of fibrosis; all of which contribute to dysregulation of the vascular endothelium.¹⁰

Similar to angiotensin II, antibodies directed against the angiotensin II type 1 receptor (AT1Rab) activate the receptor, AT1R. AT1Rabs have been detected in the sera of patients with conditions associated with development of hypertension,^{11,12} such as preeclampsia,¹³ and detected in kidney, heart, and liver transplant recipients with vascular rejection.^{14–18} Treatment protocols for patients who develop

Correspondence: Mary Carmelle Philogene (mary.philogene@redcross.org).

Initially submitted February 24, 2020; date of first revision April 14, 2020; accepted for publication April 21, 2020; online publication May 24, 2020.

¹Division of Immunogenetics, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; ²Department of Epidemiology, Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA; ³Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; ⁴Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; ⁵National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA.

© American Journal of Hypertension, Ltd 2020. All rights reserved. For Permissions, please email: journals.permissions@oup.com

allograft dysfunction following organ transplantation in the presence of AT1Rab are not well defined. A few single center studies have reported the use of angiotensin receptor blockers (ARBs), which target the AT1 receptor, as a mechanism to prevent allograft rejection.^{19,20} The effect of these and other antihypertensive medications on BP in the presence of AT1Rab is not known. In this study, we aimed to determine the prevalence of AT1Rab in community-dwelling hypertensive adults and elucidate the relationship between presence of AT1Rab and medication-specific BP regulation.

METHODS

Study population

We performed a cross-sectional analysis of data from the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study. HANDLS is a population-based cohort study examining the influence and interaction of race and socioeconomic status on the development of cardiovascular and cerebrovascular health disparities among minorities and lower socioeconomic status groups.²¹ Participants are black and white community-dwelling individuals between the ages of 30 and 64 at enrollment who are from 13 neighborhoods (group of contiguous census tracts) in both low and high socioeconomic strata in Baltimore City, MD. Participant enrollment took place from August 2004 to November 2009, and follow-up evaluations are completed every 5 years. Each participant provided written informed consent. The protocol was approved by the National Institute of Environmental Health Sciences, National Institutes of Health. In the present study, 1,006 HANDLS participants with self-reported hypertension at study baseline were included, and their sera were examined for detection of antibodies against AT1R. BP measurements collected from follow-up visits were compared with antibody levels.

Measurements

Stored sera with unique identifiers were shipped on ice from repositories located at the National Institute on Aging to the Johns Hopkins Immunogenetics Laboratory, stored at -80°C , and tested in batches over a period of 4 months. Detection of AT1Rab was performed using a validated quantitative Enzyme-linked immunosorbent assay (ELISA) (One Lambda, ThermoFisher). The samples were run in duplicate on microtiter plates coated with human AT1R derived from transfected Chinese hamster ovary cell extracts. Duplicate results with greater than 20% coefficient of variation were repeated. The presence of antibody bound to AT1R was detected by a colorimetric change. Optical density values were converted into a concentration expressed as unit per milliliter (units/ml) based on a standard curve generated using control samples at varying concentrations (2.5, 5, 10, 20, and >40 units/ml). AT1Rab was reported as positive for concentrations ≥ 17 units/ml according to the manufacturer's recommendations as well as previous reports from the Immunogenetics Laboratory at Johns Hopkins.²²

BP and uncontrolled BP were our primary outcomes of interest. Each participant underwent sitting and standing BP

measurements on each arm using the brachial artery auscultation method with an inflatable cuff of appropriate size.²³ We examined the relation of AT1Rab positivity to (i) systolic and diastolic BP (average of sitting and standing measures); (ii) uncontrolled BP defined as an average baseline systolic BP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm Hg; and (iii) uncontrolled BP by antihypertensive medication type. Medications were categorized by review of participants' self-reported medication lists. Other factors that may contribute to differences in AT1Rab status and/or BP were examined, including participants' age, sex, race, body mass index,²⁴ history of smoking, evidence of inflammation,^{25,26} and comorbid conditions such as diabetes^{8,27} and cardiovascular disease.²⁸ Age, sex, race (African American or White), and household income level were self-reported at the doorstep during household enrollment in HANDLS. The presence of relevant comorbid diseases was ascertained using medical history, physical examination, and laboratory assessment on a mobile research vehicle. Health behaviors such as tobacco use were self-reported. Diabetes mellitus was defined as fasting plasma glucose concentration ≥ 126 mg/dl (7.0 mmol/l), self-report of diabetes, or use of hypoglycemic agents. Anthropometric measurements were performed, including height and weight, and were used to calculate body mass index. Fasting venous blood was collected on the mobile research vehicle. High sensitivity C-reactive protein levels were measured from blood samples by immunoassay at the National Institute on Aging or Quest Diagnostics using similar equipment and reagents.²⁹

Statistical analysis

Differences in participant characteristics by AT1Rab status were examined using Fisher's exact tests for categorical variables and *t*-tests or Wilcoxon–Mann–Whitney test for continuous variables. Unadjusted and multivariable logistic regression models were developed to estimate the association between participant characteristics and AT1Rab status. The association between participant AT1Rab status and BP was examined using *t*-tests and linear regression models adjusting for demographic characteristics (age, sex, and race). The association between AT1Rab status and uncontrolled BP was examined using Fisher's exact tests and logistic regression adjusting for demographic characteristics. Linear regression models were developed to estimate the association between medication use and BP among AT1Rab positive and negative participants, adjusting for demographic characteristics. The association between medication use and uncontrolled BP among AT1Rab positive and negative participants was examined using logistic regression. Alpha (2-tailed) was set at <0.05 and data were analyzed using Stata 15.1 (StataCorp LLC, College Station, TX, 2017).

RESULTS

Participant characteristics overall and by AT1Rab status

Of 3,720 participants enrolled in the HANDLS study, we identified 1,006 with self-reported hypertension who had available serum for AT1Rab testing. Participant

Table 1. Demographic and clinical characteristics overall, and by AT1Rab status

Patient characteristics	N for analysis	Overall	AT1Rab positive	AT1Rab negative	P value
AT1Rab status, n (%)	1,006	—	132 (13.1)	874 (86.9)	—
Age, mean (SD)	1,006	52.4 (8.4)	52.5 (8)	52.4 (8.5)	0.86
Male, n (%)	1,006	408 (41)	57 (43.2)	351 (40.2)	0.51
White race, n (%)	1,006	383 (38.1)	62 (47)	321 (36.7)	0.03
Income below poverty level, n (%)	1,006	426 (42.4)	57 (43.2)	369 (42.2)	0.85
Former and/or current history of smoking, n (%)	991	679 (68.5)	73 (56.2)	606 (70.4)	0.002
Body mass index (kg/m ² , mean (SD))	1,006	32.4 (8.1)	31.9 (8.1)	32.5 (8.1)	0.42
Liver cirrhosis, n (%)	1,002	9 (0.9)	3 (2.3)	6 (0.7)	0.1
Congestive heart failure, n (%)	996	62 (6.2)	9 (6.9)	53 (6.1)	0.7
Coronary artery disease, n (%)	996	81 (8.1)	8 (6.1)	73 (8.4)	0.49
Atrial fibrillation, n (%)	995	131 (13.1)	21 (16)	110 (12.7)	0.33
Diabetes, n (%)	989	299 (30.2)	36 (27.9)	263 (30.6)	0.61
C-reactive protein, median (p25–p75)	982	3 (1.2–7.3)	3.5 (1.5–7.8)	2.9 (1.1–7.1)	0.15
AT1Rab concentration (units/ml, mean (SD))	1,006	4.7 to >40	>28.3 (9.6) ^a	9.4 (2.8)	—

^aWithin the AT1Rab+ group, 44 participants had very high AT1Rab concentrations with values that exceeded the maximum limit of detection of the Enzyme-linked immunosorbent assay (ELISA); these concentrations were reported as >40 units/ml.

characteristics are described in Table 1. The cohort consisted of 59% women, 62% African Americans, with a mean age at enrollment of 52 years. Overall, 132 participants (13.1%) were positive for AT1Rab (Table 1). AT1Rab+ and AT1Rab– participants were of similar age and had similar sex composition, however, compared with AT1Rab– participants, a greater proportion of AT1Rab+ participants were White (47% vs. 36.7%; $P = 0.03$); 16% (62 of 383) of White participants were AT1Rab+ while 11% of African American participants (70 of 623) were AT1Rab+. Former or current history of smoking tobacco was more common among AT1Rab– participants (70.4%) as compared with AT1Rab+ participants (56.2%); $P = 0.002$ (Table 1). In multivariable logistic regression models, White race and tobacco use had independent associations with AT1Rab status. White race was associated with greater odds of being AT1Rab+ (odds ratio 1.56, 95% confidence interval 1.05–2.31) and tobacco use was associated with lesser odds of being AT1Rab+ (odds ratio 0.52, 95% confidence interval 0.35–0.78) (Table 2). No other demographic or clinical characteristics were statistically significantly associated with AT1Rab status.

BP by AT1Rab status and antihypertensive medication

Mean systolic BP was similar between AT1Rab+ and AT1Rab– participants (127 vs. 126.3 mm Hg, respectively; $P = 0.71$); as was the prevalence of uncontrolled BP across the 2 groups (33.3% and 28.1%, respectively; $P = 0.25$) (Table 3). Conversely, the mean diastolic BP in the AT1Rab+ group was statistically significantly higher than in the AT1Rab– group (77.3 vs. 75 mm Hg; $P = 0.03$). In multivariable regression models, these relationships were similar, with a statistically significantly higher diastolic BP among AT1Rab+ participants ($P = 0.01$) (Table 4). The adjusted

Table 2. Multivariable logistic regression of variables with AT1Rab status

Variable ^a	Odds ratio comparing AT1Rab positive to negative participants	95% confidence interval
Age	1.005	0.98, 1.03
Male	1.14	0.76, 1.7
White race	1.56	1.05, 2.31
Income below poverty level	1.14	0.76, 1.7
Former and/or current history of smoking	0.52	0.35, 0.78
Body mass index (kg/m ²)	0.99	0.96, 1.01
Liver cirrhosis	2.84	0.67, 11.98
Congestive heart failure	1.22	0.56, 2.65
Coronary artery disease	0.71	0.32, 1.55
Atrial fibrillation	1.31	0.75, 2.28
Diabetes	0.86	0.55, 1.34
C-reactive protein	1.01	0.99, 1.02

^aAll variables (covariates) included.

odds ratio for uncontrolled BP was 1.33 (95% confidence interval 0.89–1.98) for AT1Rab+ vs. AT1Rab– persons.

A majority (88%) of participants reported being prescribed antihypertensive medications, which included ARBs, angiotensin-converting enzyme inhibitors (ACEis), calcium channel blockers, alpha- and beta blockers, and diuretics (full list provided in Supplementary Table S1 online). ARBs prescribed included irbesartan, valsartan, losartan, and olmesartan. Most participants were prescribed

Table 3. Absolute BP and BP control by AT1Rab status

Variable	N	Overall	AT1Rab positive	AT1Rab negative	P value
Systolic BP (mm Hg), mean (SD)	986	126.4 (18.9)	127 (18.8)	126.3 (19)	0.71 ^a
Diastolic BP (mm Hg), mean (SD)	985	75.3 (11.1)	77.3 (11.2)	75 (11.1)	0.03 ^a
Uncontrolled BP, n (%)	986	284 (28.8)	43 (33.3)	241 (28.1)	0.25 ^b

Abbreviation: BP, blood pressure.

^at-Test.

^bFisher's exact test.

Table 4. Multivariable analysis of BP measurements by AT1Rab status (positive vs. negative), adjusted for age, sex, and race

Variable	N	Beta (SE) or OR (95% CI)	P value
Systolic BP (mm Hg)	986	1.14 (1.75)	0.52 ^a
Diastolic BP (mm Hg)	985	2.61 (1.03)	0.01 ^a
Uncontrolled BP	986	1.33 (0.89, 1.98)	0.17 ^b

Both linear and logistic regression adjusted age, sex, and race. Uncontrolled BP: systolic BP \geq 140 mm Hg and/or diastolic BP \geq 90 mm Hg. Abbreviations: BP, blood pressure; CI, confidence interval; OR, odds ratio.

^aLinear regression.

^bLogistic regression.

more than 1 antihypertensive medication, with diuretics (49.8%) followed by ACEi (36.3%) being the most common. ARB prescriptions were noted for 16.3% (143 of 880) of participants. There was no statistically significant difference in medication types prescribed to participants by AT1Rab status (Supplementary Table S2 online).

In multivariable linear regression analyses, and compared with AT1Rab+ persons who were on other antihypertensive medications, AT1Rab+ persons who had been prescribed an ARB had 10.5 mm Hg higher systolic blood pressure ($P = 0.02$) and no statistically significant difference in diastolic blood pressure (mean difference 4.7 mm Hg; $P = 0.2$) (Table 5). There was a trend toward greater odds of uncontrolled BP among AT1Rab+ participants prescribed an ARB compared with those on other antihypertensive medications (adjusted odds ratio 2.05, 95% confidence interval 0.76–5.53). In contrast, there was no difference in systolic or diastolic BP among AT1Rab– participants by ARB use (Table 5).

AT1Rab+ participants prescribed an ACEi had an adjusted mean of 2.83 higher systolic BP than AT1Rab+ persons not prescribed an ACEi ($P = 0.46$) (Table 5). AT1Rab– participants prescribed an ACEi had similar systolic BP but 1.8 mm Hg lower diastolic BP than AT1Rab– persons not prescribed an ACEi ($P = 0.03$). Participant characteristics by ARB, ACEi, and all other medication use are detailed in Supplementary Table S3 online.

DISCUSSION

Among community-dwelling adults with hypertension, we found that the prevalence of AT1Rabs was 13.1%. AT1Rab+ individuals were more likely to be White and

had higher diastolic BP than those who were AT1Rab–. AT1Rab+ persons who reported taking an ARB had higher systolic BP than antibody positive individuals taking other antihypertensive medications. Among participants who were AT1Rab–, BP did not differ by ARB use, however, those prescribed an ACEi had modestly lower diastolic BP than persons not prescribed an ACEi.

Antibodies against AT1R have been identified that bind to a specific sequence within the second extracellular loop (ECL2) of the receptor.^{14,30} When bound to the ECL2, these autoantibodies were shown to cause activation of signaling through phosphorylation of the extracellular signal-regulated kinase pathway²⁰ which results in upregulation of proinflammatory targets,³¹ endothelial cell damage, and BP dysregulation. In a sample of 315 older adults, with a different ELISA which uses purified capture antigen, AFHYESQ (one of the 2 sequences required for antibody binding as was described by Dragun *et al.*²⁰), higher AT1Rab concentrations were associated with hypertension, inflammation, and frailty.²⁴ AT1Rab concentrations in the same study were higher among individuals over 70 years old than among younger individuals. Here, we report, in a larger and younger population (median age of 52 years) with hypertension, that there was a trend toward AT1Rab+ individuals being more likely to have uncontrolled BP as compared with AT1Rab– persons (33% vs. 28%, respectively). Mikolajczyk *et al.* recently summarized the evidence for the role of the adaptive immune response and hypertension.¹²

In our analyses by antihypertensive medication type, we noted variation in BP for AT1Rab+ participants depending upon whether they were treated with an ARB or another antihypertensive. Many of the ARBs target residues within the ECL2 region of AT1R and block the activation of the receptor.³² The effect of AT1Rab on arterial contraction has been illustrated in animal models, as has the response to ARBs. AT1Rabs cause increased arterial contractility in rats, which can be blocked with losartan.³³ Abadir *et al.* further showed that treatment with ARBs was associated with better control of systolic BP in patients with higher AT1Rab levels compared with patients with low AT1Rab.²⁴ Taking this existing literature together, we expected to find that AT1Rab+ persons in our study who were prescribed an ARB would have better BP control, however we found the converse. Notably, studies that have evaluated the interaction between the AT1R and a number of ARBs, have found differences in the ability of individual ARBs to effectively inactivate AT1R.^{18,34} For example, candesartan has been reported to be more effective compared with losartan in treatment of patients with

Table 5. Association between prescribed antihypertensive medication and BP by AT1Rab status

Predictor	N ^a	Outcome	Beta (SE) ^b	P value	Uncontrolled BP (OR, 95% CI)
AT1Rab positive					
ARB use	115	SBP	10.52 (4.56)	0.02	2.05 (0.76, 5.53)
	115	DBP	4.74 (2.71)	0.21	
ACEi use	115	SBP	2.83 (3.84)	0.46	0.75 (0.31, 1.78)
	115	DBP	0.17 (2.27)	0.94	
AT1Rab negative					
ARB use	745	SBP	0.58 (1.84)	0.75	0.97 (0.62, 1.52)
	744	DBP	1.05 (1.07)	0.33	
ACEi use	746	SBP	-1.24 (1.39)	0.37	0.98 (0.69, 1.38)
	745	DBP	-1.82 (0.81)	0.03	

Linear regression models adjusted for age, sex, and race. Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CI, confidence interval; DBP, diastolic blood pressure; OR, odds ratio; SBP, systolic blood pressure.

^aNumber of outcomes (SBP and DBP) with ARB/ACEi by AT1Rab status.

^bStandard error.

vascular-mediated solid organ transplant rejection because of higher AT1R avidity and half-life.³⁴ Furthermore, mutant models of AT1R that resemble the active conformational structure of this receptor, showed that epitopes that are targeted by losartan become inaccessible in a constitutively active form of AT1R compared with a receptor that alternates between resting and active state.³⁴ With a modest number of AT1Rab+ participants prescribed an ARB ($n = 143$), we were unable to explore the effects of different ARBs on BP, thus larger studies of this subject are warranted and could have important therapeutic implications.

Interestingly, a few studies have shown that AT1Rab may also affect intracellular calcium concentrations independent of the known target receptor, AT1R.^{35,36} Wang *et al.*³⁵ show that in BALB/C mice injected with AT1Rab and exhibiting phenotypes similar to preeclampsia (i.e., development of hypertension and proteinuria), there was a decrease in the expression of potassium calcium channels which are important for regulation of intracellular Ca²⁺ concentration. The use of valsartan, an ARB, did not show improvement in the phenotypes of these preeclamptic animals. Yu *et al.*³⁶ further showed that AT1Rab isolated from patients with preeclampsia and incubated in a preeclampsia podocyte injury rat model resulted in a dose dependent induced podocyte injury and changes in intracellular Ca²⁺ concentration.³⁶ Of note, in our study, when participants expressed AT1Rab, BP control was better among those prescribed other medications as compared with those prescribed an ARB.

The characteristics of participants on an ARB were similar to those on other medications, with slightly higher body mass index and more females among those reporting ARB use. Many of these antihypertensive drugs target pathways that are independent of renin and angiotensin system (calcium channel blockers and beta blockers) or work upstream of the AT1R. For example, ACEis prevent formation of the natural ligand angiotensin II. Recent studies have shown improved outcomes in the treatment for hypertension with use of new combination drugs.³⁷ Future studies are needed that are inclusive of adequate numbers of participants

with and without AT1Rab and treated with a diversity of antihypertensives medications in order to advance understanding of the appropriate treatment for hypertension in the setting of AT1Rabs.

In our study, White race was a predictor of AT1Rab positivity. Whether this is due to genetic ancestry more common among individuals who self-identify as White is unknown. Allele variants of AT1R have been identified and these variants are associated with variable increase in receptor expression.^{38–40} It is possible that during an inflammatory event that causes endothelial cell damage, individuals with higher AT1R expression would present autoantigens and develop autoantibodies. Further work is needed to assess the role of allele expression based on genetic ancestry in this process.

Our study had limitations, including (i) its cross-sectional design, (ii) the limited number of AT1Rab+ participants taking ARBs and other antihypertensive medications to allow for a more detailed analysis across medication types, and (iii) the lack of a measure of adherence to reported medications. We employed a commonly used and validated commercial assay to measure AT1Rabs based on immunoreactivity to full length AT1R. The Johns Hopkins Immunogenetics Laboratory, in collaboration with 10 other laboratories through proficiency testing has established the rate of concordance as 90% with the 10% discordant results due to variations between the negative vs. borderline cutoffs as determined by the manufacturer of the assay (10–17 units/ml is considered borderline). The assay measures the quantity of the autoantibodies but does not address their biological activity. Work by Dragun *et al.* and other investigative teams have described an agonistic activity to AT1Rabs based on using enriched IgG fractions from patients positive for AT1Rabs in either competition assays, cell-based readouts in the presence or absence of ARBs, or for injection into mice.^{19,20,31,35} Therefore, further basic research is required to map out the mechanism of action of these antibodies.

Strengths of our study include it being, to our knowledge, the first to investigate the prevalence of AT1Rab in

community-dwelling hypertensive individuals. We were also able to explore the relation of medication type to BP control by AT1Rab status which can serve to generate hypotheses for future work in this area.

In conclusion, we found AT1Rabs to be prevalent among a sample of individuals with hypertension, and also found that BP control among AT1Rab+ persons varied by medication type. Toward greater precision in hypertension treatment, we identified an immunologic factor that may affect BP regulation in a subset of individuals and is worthy of further study.

SUPPLEMENTARY MATERIAL

Supplementary data are available at *American Journal of Hypertension* online.

FUNDING

This research was funded by a grant from the National Kidney Foundation of Maryland.

DISCLOSURE

The authors declared no conflict of interest.

REFERENCES

- Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. *J Manag Care Pharm* 2007; 13:9–20.
- James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Oggedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 2014; 311:507–520.
- Smith DK, Lennon RP, Carlsgaard PB. Managing hypertension using combination therapy. *Am Fam Physician* 2020; 101:341–349.
- Leete J, Gurley S, Layton A. Modeling sex differences in the renin-angiotensin system and the efficacy of antihypertensive therapies. *Comput Chem Eng* 2018; 112:253–264.
- Schelleman H, Chen J, Chen Z, Christie J, Newcomb CW, Brensinger CM, Price M, Whitehead AS, Kealey C, Thorn CF, Samaha FF, Kimmel SE. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. *Clin Pharmacol Ther* 2008; 84:332–339.
- Schelleman H, Klungel OH, Wittman JC, Breteler MM, Hofman A, van Duijn CM, de Boer A, Stricker BH. Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke. *Pharmacogenomics J* 2008; 8:400–407.
- Schelleman H, Limdi NA, Kimmel SE. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. *Pharmacogenomics* 2008; 9:1331–1346.
- Strauss MH, Hall AS. The divergent cardiovascular effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in adult patients with type 2 diabetes mellitus. *Can J Diabetes* 2018; 42:124–129.
- Zhu M-L, Sun R-L, Zhang H-Y, Zhao F-R, Pan G-P, Zhang C, Song P, Li P, Xu J, Wang S, Yin Y-L. Angiotensin II type 1 receptor blockers prevent aortic arterial stiffness in elderly patients with hypertension. *Clin Exp Hypertens* 2019; 41:657–661.
- Chao Y, Zhu L, Qu X, Zhang J, Zhang J, Kong X, Gu Y, Pu J, Wu W, Ye P, Luo J, Yang H, Chen S. Inhibition of angiotensin II type 1 receptor reduced human endothelial inflammation induced by low shear stress. *Exp Cell Res* 2017; 360:94–104.
- LaMarca B, Parrish M, Ray LF, Murphy SR, Roberts L, Glover P, Wallukat G, Wenzel K, Cockrell K, Martin JN Jr, Ryan MJ, Dechend R. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. *Hypertension* 2009; 54:905–909.
- Mikolajczyk TP, Guzik TJ. Adaptive immunity in hypertension. *Curr Hypertens Rep* 2019; 21:68.
- Wallukat G, Neichel D, Nissen E, Homuth V, Luft FC. Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia. *Can J Physiol Pharmacol* 2003; 81:79–83.
- Dragun D. Agonistic antibody-triggered stimulation of Angiotensin II type 1 receptor and renal allograft vascular pathology. *Nephrol Dial Transplant* 2007; 22:1819–1822.
- Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. *J Clin Invest* 1999; 103:945–952.
- Delville M, Lamarthée B, Pagie S, See SB, Rabant M, Burger C, Gault P, Giral M, Thauant O, Arzouk N, Hertig A, Hazzan M, Matignon M, Mariat C, Caillard S, Kamar N, Sayegh J, Westeel PF, Garrouste C, Ladrière M, Vuiblet V, Rivalan J, Merville P, Bertrand D, Le Moine A, Van Huyen JPD, Cesbron A, Cagnard N, Alibeu O, Satchell SC, Legendre C, Zorn E, Taupin JL, Charreau B, Anglicheau D. Early acute microvascular kidney transplant rejection in the absence of anti-HLA antibodies is associated with preformed IgG antibodies against diverse glomerular endothelial cell antigens. *J Am Soc Nephrol* 2019; 30:692–709.
- Villa C, Mesa K, Cristy Smith M, Mooney DM, Coletti A, Klohe E. Hyperacute graft dysfunction in an orthotopic heart transplant in the presence of non-HLA antibodies. *Am J Transplant* 2020; 20:593–599.
- Philogene MC, Johnson T, Vaught AJ, Zakaria S, Fedarko N. Antibodies against angiotensin II Type 1 and endothelin receptors: relevance and pathogenicity. *Hum Immunol* 2019; 80:561–567.
- Carroll RP, Riceman M, Hope CM, Zeng A, Deayton S, Bennett GD, Coates PT. Angiotensin II type-1 receptor antibody (AT1Rab) associated humoral rejection and the effect of peri operative plasma exchange and candesartan. *Hum Immunol* 2016; 77:1154–1158.
- Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebcke J, Eckert D, Mazak I, Plehm R, Schönemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. *N Engl J Med* 2005; 352:558–569.
- Evans MK, Lepkowski JM, Powe NR, LaVeist T, Kuczmarski MF, Zonderman AB. Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS): overcoming barriers to implementing a longitudinal, epidemiologic, urban study of health, race, and socioeconomic status. *Ethn Dis* 2010; 20:267–275.
- Philogene MC, Bagnasco S, Kraus ES, Montgomery RA, Dragun D, Leffell MS, Zachary AA, Jackson AM. Anti-angiotensin II type 1 receptor and anti-endothelial cell antibodies: a cross-sectional analysis of pathological findings in allograft biopsies. *Transplantation* 2017; 101:608–615.
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 2003; 42:1206–1252.
- Abadir PM, Jain A, Powell LJ, Xue QL, Tian J, Hamilton RG, Bennett DA, Finucane T, Walston JD, Fedarko NS. Discovery and validation of agonistic angiotensin receptor autoantibodies as biomarkers of adverse outcomes. *Circulation* 2017; 135:449–459.

25. Pearl MH, Zhang Q, Palma Diaz MF, Grotts J, Rossetti M, Elashoff D, Gjertson DW, Weng P, Reed EF, Tsai Chambers E. Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation. *Kidney Int* 2018; 93:260–269.
26. Pearl MH, Grotts J, Rossetti M, Zhang Q, Gjertson DW, Weng P, Elashoff D, Reed EF, Tsai Chambers E. Cytokine profiles associated with angiotensin II type 1 receptor antibodies. *Kidney Int Rep* 2019; 4:541–550.
27. Xu H-Z, Cheng Y-L, Wang W-N, Wu H, Zhang Y-Y, Zang C-S, Xu Z-G. 12-Lipoxygenase inhibition on microalbuminuria in type-1 and type-2 diabetes is associated with changes of glomerular angiotensin II type 1 receptor related to insulin resistance. *Int J Mol Sci* 2016; 17:684. doi:10.3390/ijms17050684.
28. Hao WW, Zhang SL, Sun Y, Bai LN, Bian JW, Yu HC, Yin XC, Wang PL, Liu HR. [Angiotensin II type 1 receptor autoantibody induces myocardial fibrosis by activating cardiac fibroblasts]. *Sheng Li Xue Bao* 2018; 70:343–353.
29. Waldstein SR, Moody DLB, McNeely JM, Allen AJ, Sprung MR, Shah MT, Al'Najjar E, Evans MK, Zonderman AB. Cross-sectional relations of race and poverty status to cardiovascular risk factors in the Healthy Aging in Neighborhoods of Diversity across the Lifespan (HANDLS) study. *BMC Public Health* 2016; 16:258.
30. Zhang H, Unal H, Gati C, Han GW, Liu W, Zatsepin NA, James D, Wang D, Nelson G, Weierstall U, Sawaya MR, Xu Q, Messerschmidt M, Williams GJ, Boutet S, Yefanov OM, White TA, Wang C, Ishchenko A, Tirupula KC, Desnoyer R, Coe J, Conrad CE, Fromme P, Stevens RC, Katritch V, Karnik SS, Cherezov V. Structure of the Angiotensin receptor revealed by serial femtosecond crystallography. *Cell* 2015; 161:833–844.
31. Günther J, Kill A, Becker MO, Heidecke H, Rademacher J, Siegert E, Radić M, Burmester GR, Dragun D, Riemekasten G. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. *Arthritis Res Ther* 2014; 16:R65.
32. Takezako T, Unal H, Karnik SS, Node K. Structure-function basis of attenuated inverse agonism of angiotensin II type 1 receptor blockers for active-state angiotensin II type 1 receptor. *Mol Pharmacol* 2015; 88:488–501.
33. Kem DC, Li H, Velarde-Miranda C, Liles C, Vanderlinde-Wood M, Galloway A, Khan M, Zillner C, Benbrook A, Rao V, Gomez-Sanchez CE, Cunningham MW, Yu X. Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism. *J Clin Endocrinol Metab* 2014; 99:1790–1797.
34. Takezako T, Unal H, Karnik SS, Node K. Current topics in angiotensin II type 1 receptor research: focus on inverse agonism, receptor dimerization and biased agonism. *Pharmacol Res* 2017; 123:40–50.
35. Wang P, Zhang S, Ren J, Yan L, Bai L, Wang L, Wang P, Bian J, Yin X, Liu H. The inhibitory effect of BKCa channels induced by autoantibodies against angiotensin II type 1 receptor is independent of AT1R. *Acta Biochim Biophys Sin (Shanghai)* 2018; 50:560–566.
36. Yu Y, Zhang L, Xu G, Wu Z, Li Q, Gu Y, Niu J. Angiotensin II type I receptor agonistic autoantibody induces podocyte injury via activation of the TRPC6- calcium/calciueurin pathway in pre-eclampsia. *Kidney Blood Press Res* 2018; 43:1666–1676.
37. Wehland M, Simonsen U, Buus NH, Kruger M, Grimm D. An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension. *Expert Opin Pharmacother*, published online March 5 2020 (doi:10.1126/science.1054678).
38. Hsu CC, Bray MS, Kao WH, Pankow JS, Boerwinkle E, Coresh J. Genetic variation of the renin-angiotensin system and chronic kidney disease progression in black individuals in the atherosclerosis risk in communities study. *J Am Soc Nephrol* 2006; 17:504–512.
39. Jones A, Dhamrait SS, Payne JR, Hawe E, Li P, Toor IS, Luong L, Wootton PT, Miller GJ, Humphries SE, Montgomery HE. Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. *Hypertension* 2003; 42:500–506.
40. Niu W, Qi Y. Association of the angiotensin II type I receptor gene +1166 A>C polymorphism with hypertension risk: evidence from a meta-analysis of 16474 subjects. *Hypertens Res* 2010; 33:1137–1143.

Supplemental Table 1: Participants' Anti-hypertensive Medications by Class

ARB	ACE inhibitor	Calcium Channel Blocker	Beta Blocker	Thiazide diuretic	K sparing diuretic	Loop Diuretic	Carbonic anhydrase inhibitors
Avapro Benicar Cozaar Diovan Ibersartan Losartan Micardis Olmesartan	Accupril Altace Benazepril Hcl Captopril Enalapril Fosinopril Lisinopril Lotensin Moexipril Prinivil Quinapril Vasotec Zestril	Adalat Afeditab CR Amlodipine Caduet Calan Cardizem Cartia XL Dynacirc Felodipine Nifedical XL Nifedipine Nifedipine ER Norvsac Plendil Procardia Procardia XL Sular Verapamil Verelan	Atenolol Bisoprolol Carvedilol Coreg Labetalol Lopressor Metoprolol Metoprolol succinate Metoprolol tartrate Nadolol Propranolol Sotalol Tenormin Toprol XL	Chlorthalidone Hydrochlorothiazide Indapamide Lozol Metolazone	Aldactone Dyazide Spironolactone Triamterene	Dyazide Furosemide Lasix	Methazolamide
Nitrates	Central alpha agonist	Alpha blocker	Vasodilator	ARB + Thiazide Diuretic	ACEI + Thiazide Diuretic	Thiazide + K sparing diuretic	Calcium channel blocker + ACEI
Imdur Isosorbide Dinitrate Isosorbide Mononitrate	Catapres Clonidine	Doxazosin Hytrin Terazosin	Hydralazine Minoxidil	Avalide Benicar HCT Diovan HCT Hyzaar Micardis HCT Teveten HCT	Benazepril HCT Prinzide Uniretic	Dyazide Maxzide	Lotrel Tarka

Supplemental Table 2: Reported use of anti-hypertensive medication by AT1RAb status

Medication classification, n (%)	N	Overall	AT1RAb positive	AT1RAb negative	p-value
Angiotensin receptor blockers (ARB)	880	143 (16.3)	21 (17.8)	122 (16)	0.59
Angiotensin converting enzyme inhibitors (ACEi)	881	320 (36.3)	37 (31.4)	283 (37.1)	0.26
Diuretics	881	439 (49.8)	61 (51.7)	378 (49.5)	0.69
Calcium channel blockers	881	222 (25.2)	22 (18.6)	200 (26.2)	0.09
Alpha Agonists	881	19 (2.2)	2 (1.7)	17 (2.2)	1.00
Beta blockers	881	247 (28)	29 (24.6)	218 (28.6)	0.44
No blood pressure medications	881	114 (12.9)	20 (17)	94 (12.3)	0.18

Supplemental Table 3: Participant characteristics by anti-hypertensive medication use

Variable	ARB	ACEi	All other medications
	n, Mean(SD)	n, Mean(SD)	n, Mean(SD)
Age	143, 55.2 (6.97)	320, 53.7 (8.05)	424, 61.9 (8.08)
BMI	143, 34.8 (8.35)	320, 32.9 (7.7)	424, 31.8 (8.22)
CRP (n, Median(p25-p75)	139, 3.2 (1.4-8.4)	314, 3.2 (1.3-7.1)	410, 2.8 (1.1-6.9)
	n (%)	n (%)	n (%)
Women	94 (65.73)	179 (55.94)	261(61.56)
White race	54 (37.76)	133 (41.56)	151(35.61)
AT1RAb positive	21 (14.69)	37 (11.56)	61 (14.39)
Uncontrolled hypertension	43 (30.5)	84 (26.84)	110 (26.63)
Albuminuria	29 (26.85)	56 (25.34)	36 (12.86)
Congestive heart failure	5 (3.5)	34 (10.76)	22 (5.26)
Liver Cirrhosis	1 (0.7)	2 (0.63)	6 (1.42)
Coronary artery disease	6 (4.2)	39 (12.34)	32 (7.66)
History of smoking	90 (63.83)	213 (67.19)	290 (70.05)
Pre-diabetes	26 (18.44)	56 (17.89)	89 (21.34)
Diabetes	62 (43.97)	152 (48.56)	73 (17.51)